Balchem (BCPC) Set to Announce Earnings on Friday

Balchem (NASDAQ:BCPC) will be releasing its earnings data before the market opens on Friday, May 3rd. Analysts expect Balchem to post earnings of $0.95 per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Balchem (NASDAQ:BCPC) last announced its earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. Balchem had a return on equity of 10.69% and a net margin of 11.77%. The business had revenue of $228.70 million for the quarter, compared to analyst estimates of $234.66 million. During the same quarter last year, the firm earned $0.66 EPS. Balchem’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts expect Balchem to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Balchem Stock Performance

Shares of NASDAQ BCPC opened at $143.82 on Thursday. The company has a current ratio of 2.12, a quick ratio of 1.38 and a debt-to-equity ratio of 0.31. Balchem has a 12 month low of $110.74 and a 12 month high of $159.52. The stock has a 50 day moving average of $151.33 and a 200-day moving average of $140.37. The company has a market capitalization of $4.66 billion, a P/E ratio of 42.93, a P/E/G ratio of 3.09 and a beta of 0.71.

Insiders Place Their Bets

In related news, SVP Michael Robert Sestrick sold 11,100 shares of the company’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the sale, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, SVP Michael Robert Sestrick sold 11,100 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total value of $1,700,631.00. Following the completion of the sale, the senior vice president now directly owns 6,736 shares of the company’s stock, valued at $1,032,022.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO William A. Backus sold 7,000 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $155.19, for a total value of $1,086,330.00. Following the sale, the chief accounting officer now directly owns 5,914 shares of the company’s stock, valued at $917,793.66. The disclosure for this sale can be found here. Insiders sold a total of 76,630 shares of company stock valued at $11,843,249 in the last 90 days. Corporate insiders own 1.77% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.